Camden National Bank cut its position in Becton, Dickinson and Company (NYSE:BDX) by 1.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 49,468 shares of the medical instruments supplier’s stock after selling 715 shares during the quarter. Becton, Dickinson and comprises 3.0% of Camden National Bank’s holdings, making the stock its 7th biggest position. Camden National Bank’s holdings in Becton, Dickinson and were worth $9,652,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of BDX. BlackRock Inc. lifted its position in Becton, Dickinson and by 2,427.8% in the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after purchasing an additional 15,887,611 shares during the last quarter. Vanguard Group Inc. lifted its position in Becton, Dickinson and by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after purchasing an additional 796,034 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Becton, Dickinson and in the 1st quarter valued at about $101,993,000. Waverton Investment Management Ltd bought a new stake in Becton, Dickinson and in the 2nd quarter valued at about $68,448,000. Finally, Montag & Caldwell LLC lifted its position in Becton, Dickinson and by 173.1% in the 2nd quarter. Montag & Caldwell LLC now owns 516,821 shares of the medical instruments supplier’s stock valued at $100,837,000 after purchasing an additional 327,587 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 75,904 shares of company stock worth $15,242,688. Corporate insiders own 1.40% of the company’s stock.

BDX has been the topic of a number of recent analyst reports. Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their price target for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. Bank of America Corporation restated a “buy” rating and set a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Piper Jaffray Companies restated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research report on Monday, July 17th. Finally, BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and a consensus price target of $196.93.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/17/becton-dickinson-and-company-bdx-is-camden-national-banks-7th-largest-position.html.

Becton, Dickinson and Company (NYSE BDX) opened at 195.34 on Friday. The stock has a 50 day moving average of $199.43 and a 200 day moving average of $191.33. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm has a market cap of $44.45 billion, a PE ratio of 56.57 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same period in the prior year, the company posted $2.35 EPS. The company’s revenue was down 5.1% compared to the same quarter last year. Analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be given a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.49%. Becton, Dickinson and’s payout ratio is presently 83.43%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.